Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo-controlled study

Journal of Clinical Lipidology

Volumn 8, Issue 6, 2014, Pages 568-575

  Moriarty, Patrick M ^a   Roth, Eli M ^b   Karns, Adam ^c   Ye, Ping ^d   Zhao, Shui Ping ^e   Liao, Yuhua ^f   Capuzzi, David M ^g   Bays, Harold E ^h   Zhang, Fumin ⁱ   Liu, Shaowen ^j   Reichman, Alan J ^k   Brusco, Osvaldo A ^l   Lu, Guoping ^m   Lerman, Sam ⁿ   Duan, Zhenwen ^o   Guo, Shuren ^o   Liu, Ping Lan ^o   Zhao, Junxian ^o   Zhang, Yan ^o   Li, Simon ^p  

^a UNIVERSITY OF KANSAS   (United States)

^b Sterling Research Group   (United States)

^c Karns Medical Corporation   (United States)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

^f UNION HOSPITAL   (China)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

ⁱ THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^j SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^k Clinical Trials Program   (United States)

^l TEXAS A M COLLEGE OF MEDICINE   (United States)

^m SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

ⁿ MEMORIAL REGIONAL HOSPITAL   (United States)

^o Luye Pharma Group   (China)

^p Luye Pharma Group   (United States)

more..

Author keywords

Atherosclerosis; Cholesterol; Lovastatin; Red yeast rice; Xuezhikang

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; XUEZHIKANG; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; BIOLOGICAL PRODUCT; CHOLESTIN; HERBACEOUS AGENT; MEVINOLIN;

ABDOMINAL DISCOMFORT; ABNORMAL FECES COMPOSITION; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INSOMNIA; JAW PAIN; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; MYOPATHY; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THYROID CANCER; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGED; BLOOD; CHINA; CLINICAL TRIAL; DYSLIPIDEMIAS; GASTROINTESTINAL DISEASES; IMMUNOLOGY; MIDDLE AGED; UNITED STATES;

ADULT; AGED; APOLIPOPROTEINS A; APOLIPOPROTEINS B; BIOLOGICAL PRODUCTS; CHINA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUGS, CHINESE HERBAL; DYSLIPIDEMIAS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; LOVASTATIN; MALE; MIDDLE AGED; PLACEBOS; TRIGLYCERIDES; UNITED STATES;

EID: 84917729636     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.09.002     Document Type: Article

References (24)

1. J.P. Kelly, D.W. Kaufman, K. Kelley, L. Rosenberg, T.E. Anderson, and A.A. Mitchell Recent trends in use of herbal and other natural products Arch Intern Med 165 2005 281 286
2. C.W. Yang, and S.A. Mousa The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders Complement Ther Med 20 2012 466 474
3. J. Liu, J. Zhang, Y. Shi, S. Grimsgaard, T. Alraek, and V. Fønnebø Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials Chin Med 1 2006 4
4. J.J. Li, S.S. Hu, C.H. Fang, and et al. Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina Clin Chim Acta 352 2005 217 224
5. J.J. Li, Z.L. Lu, W.R. Kou, and et al. Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: a post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS) Int J Cardiol 154 2012 362 365
6. J.J. Li, Z.L. Lu, W.R. Kou, and et al. Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS) Clin Exp Hypertens 32 2010 491 498
7. M.P. Bogsrud, L. Ose, G. Langslet, and et al. HypoCol (red yeast rice) lowers plasma cholesterol: a randomized placebo controlled study Scand Cardiovasc J 44 2010 197 200
8. J.J. Li, Z.L. Lu, W.R. Kou, and et al. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS) Ann Med 42 2010 231 240
9. Z. Lu, W. Kou, B. Du, and et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction Am J Cardiol 101 2008 1689 1693
10. S.P. Zhao, Z.L. Lu, B.M. Du, and et al. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China Coronary Secondary Prevention Study (CCSPS) J Cardiovasc Pharmacol 49 2007 81 84
11. J.J. Li, Y. Wang, S.P. Nie, and et al. Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improves exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X Int J Cardiol 122 2007 82 84
12. C.L. Hu, Y.B. Li, Y.H. Tang, and et al. Effects of withdrawal of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with coronary artery disease Cardiovasc Drugs Ther 20 2006 185 191
13. C.C. Lin, T.C. Li, and M.M. Lai Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia Eur J Endocrinol 153 2005 679 686
14. S.P. Zhao, L. Liu, Y.C. Cheng, and Y.L. Li Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease Atherosclerosis 168 2003 375 380
15. M.H. Davidson, P. Toth, S. Weiss, and et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia Clin Cardiol 24 2001 467 474
16. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2000 207 213
17. P. Jones, S. Kafonek, I. Laurora, and D. Hunninghake Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am J Cardiol 81 1998 582 587
18. J.R. Downs, M. Clearfield, S. Weis, and et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
19. C.H. Chen, J.C. Yang, Y.S. Uang, and C.J. Lin Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products Int J Pharm 444 2013 18 24
20. Z. Li, N.P. Seeram, R. Lee, and et al. Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers J Altern Complement Med 11 2005 1031 1038
21. D.J. Becker, R.Y. Gordon, S.C. Halbert, B. French, P.B. Morris, and D.J. Rader Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial Ann Intern Med 150 2009 830 839
22. S.C. Halbert, B. French, R.Y. Gordon, and et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance Am J Cardiol 105 2010 198 204
23. K.E. Hansen, J.P. Hildebrand, E.E. Ferguson, and J.H. Stein Outcomes in 45 patients with statin-associated myopathy Arch Intern Med 165 2005 2671 2676
24. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 25 Suppl 2 2014 S1 S45